Chinese inhibitor drug candidate becomes first to enter phase
Time:2024-05-21 10:33:59 Source:opinionsViews(143)
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
You may also like
- Why US Catholics are planning pilgrimages in communities across the nation
- Mediaworks data breach: Hackers email victims, demanding $820
- Facing moral questions in a time of 'massive, collective structural problems'
- Opportunities Party leader Raf Manji resigns
- Saudi Arabia is going to sponsor the WTA women's tennis rankings under a new partnership
- Literacy, numeracy tests as NCEA requirement 'detrimental' to learners
- Victorian miner killed in Ballarat Gold Mine rockfall as investigation continues
- Ministry of Health 'taking the time to get it right' on puberty blockers
- Yvette Fielding says her Most Haunted co